Comments
The shares of Alembic Pharmaceuticals gained as much as 6 per cent to Rs 943.80 on Tuesday.
Earlier today, the company announced it had received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Deferasirox Tablets, 180 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product, Jadenu tablets, 180 mg, of Novartis Pharmaceuticals. Deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions.
The estimated market size for this product is US$ 53 million for twelve months ending March 2020, according to IQVIA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.